Completed PHASE3 INTERVENTIONAL 2-arm NCT00421200

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

A Randomized, Double-blind, Phase III Study of the Efficacy and Safety of an Oxygen-carrying Plasma Expander, Hemospan®, Compared With Voluven® to Prevent Hypotension in Patients Undergoing Primary Hip Arthroplasty With Spinal Anesthesia

Sponsor: Sangart

Conditions Hypotension Ischemia

Interventions Hemospan (MP4OX) Voluven (HES 130/0.4)

Updated 6 times since 2017 Last updated: Aug 15, 2013 Started: Feb 28, 2007 Primary completion: May 31, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hypotension and Ischemia and is currently completed. Sangart leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sangart

Data source: Sangart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Antwerp, Belgium , Brussels, Belgium , Genk, Belgium , Ghent, Belgium , Hradec Králové, Czechia , Kladno, Czechia , Lublin, Poland , Nijmegen, Netherlands , Nottingham, United Kingdom , Piekary Śląskie, Poland and 5 more locations